01Does the cough clear if the tablet stays?
The precaution says the cough resolved after discontinuation. It does not promise that it fades if you keep swallowing. Lowering a dose is a clinician experiment, not a labelled home taper for cough. Honey, lozenges, and a humidifier do not close the differential.
A cough that started years into a stable 10 mg plan still belongs on that differential. Time on the tablet does not grant immunity. A cough that started the week after a viral illness may still be the tablet, or may not. That is why it sits on a differential, not on an automatic stop.
02Who decides whether to switch off enalapril?
The clinician who owns the blood pressure and, if it is on the chart, the heart-failure plan. Stopping the tablet to test the cough is a supervised stop, because pressure and heart-failure symptoms can move the other way. Rebound pressure is a clinic problem, not a pharmacy-aisle problem.
This page does not name a replacement class or a washout recipe. One INN sits here. The switch, if any, is written on a new line. Do not borrow a relative's different blood-pressure tablet to 'see if the cough leaves.'
03What kind of cough does the label name?
A persistent nonproductive cough. The write-up treats it as a class effect of ACE inhibitors, presumably from bradykinin that is not broken down as usual. It always resolved after discontinuation in that precaution. It is not written as a mucus cough or as a feverish chest cold.
ACE-inhibitor cough belongs on the differential of a cough that will not quit. The potassium page is a different lab problem. The enalapril shelf does not turn a dry cough into a refill reason. Time on 10 mg does not retire that differential.
04Is a productive winter cough the same listed effect?
The listed effect is persistent and nonproductive. A wet cough with fever, or a cough that brings up sputum after a cold, may be infection or something else on the differential. The precaution still says include the ACE inhibitor when the cough will not quit. Black patients have been reported to have a higher angioedema rate on ACE inhibitors - that is swelling, not this dry cough.
Angioedema is a different stop: swelling of face, lips, tongue, or gut pain from intestinal angioedema. Intestinal cases presented with abdominal pain, with or without nausea, and sometimes without a prior facial episode. That is not a cough you wait out.
05How often did that cough show in the hypertension trials?
Cough was listed in 1.3 percent of people on Vasotec in the hypertension table, with 0.1 percent stopping for it. Placebo sat at 0.9 percent. Those tables counted events in more than one percent of people. Headache sat at 5.2 percent and dizziness at 4.3 percent on the same Vasotec hypertension list - louder than cough, and headache was higher on placebo.
Vasotec was evaluated for safety in more than 10,000 people, including over 1,000 treated for a year or more. Controlled work included 2,987 people. Discontinuation for any clinical adverse experience was 3.3 percent in hypertension. Frequency was not tied to total daily dose inside the usual ranges.
06Did heart-failure trials see the same rate?
Cough sat at 2.2 percent on Vasotec in the heart-failure adverse-experience table and 0.6 percent on placebo. Discontinuation for cough in that table was listed at 0.0 percent on the drug arm. Dizziness sat at 7.9 percent and hypotension at 6.7 percent - louder numbers, different problems.
A higher rate on a sicker cohort does not make the cough a heart-failure symptom. The precaution still says consider the tablet on the differential. Heart-failure discontinuation for any clinical adverse experience was 5.7 percent, still not a cough-specific stop rate.